These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 25111427

  • 1. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
    Krieg SM, Sonanini S, Plesnila N, Trabold R.
    J Neurotrauma; 2015 Feb 15; 32(4):221-7. PubMed ID: 25111427
    [Abstract] [Full Text] [Related]

  • 2. Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice.
    Trabold R, Krieg S, Schöller K, Plesnila N.
    J Neurotrauma; 2008 Dec 15; 25(12):1459-65. PubMed ID: 19118456
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury.
    Kleindienst A, Dunbar JG, Glisson R, Marmarou A.
    Acta Neurochir (Wien); 2013 Jan 15; 155(1):151-64. PubMed ID: 23188468
    [Abstract] [Full Text] [Related]

  • 12. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
    Méchaly I, Laurent F, Portet K, Serrano J, Cros G.
    Eur J Pharmacol; 1999 Nov 03; 383(3):287-90. PubMed ID: 10594321
    [Abstract] [Full Text] [Related]

  • 13. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.
    Prog Brain Res; 2002 Nov 03; 139():197-210. PubMed ID: 12436936
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased expression of vasopressin v1a receptors after traumatic brain injury.
    Szmydynger-Chodobska J, Chung I, Koźniewska E, Tran B, Harrington FJ, Duncan JA, Chodobski A.
    J Neurotrauma; 2004 Aug 03; 21(8):1090-102. PubMed ID: 15319008
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
    Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, Steinwall M.
    Br J Obstet Gynaecol; 1999 Oct 03; 106(10):1047-53. PubMed ID: 10519430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.